Clinical Trials Logo

Select Advanced Solid Tumors clinical trials

View clinical trials related to Select Advanced Solid Tumors.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03973333 Terminated - Clinical trials for Select Advanced Solid Tumors

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Start date: May 17, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

IMC-C103C is an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen MAGE-A4. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-C103C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for MAGE-A4.

NCT ID: NCT03515551 Terminated - Clinical trials for Select Advanced Solid Tumors

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

Start date: June 15, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

IMCnyeso is a bispecific fusion protein designed for the treatment of cancers that express NY-ESO-1 and/or LAGE-1A. This was a first-in-human trial designed to evaluate the safety and efficacy of IMCnyeso in HLA-A*02:01-positive adult participants whose cancer is positive for NY-ESO-1 and/or LAGE-A1.